Fig. 5From: Analytic validity of DecisionDx-Melanoma, a gene expression profile test for determining metastatic risk in melanoma patientsTechnical experience of the DecisionDx-Melanoma test for samples submitted from March 2013 to June 2016. Quality control rejections, technical failures and successfully tested samples are presented for the time periods before and after the reduction in required tumor density, implemented after successful clinical validation and through educational efforts to improve biopsy tissue preservation at the dermatopathology levelBack to article page